Recombinant Mouse BTNL2/BTL-II Protein, N-His

Description of Recombinant Mouse BTNL2/BTL-II Protein, N-His

Introduction

Recombinant Mouse BTNL2/BTL-II Protein is a type of protein that is produced through genetic engineering techniques, specifically through the process of recombinant DNA technology. This protein is a member of the B7 family of proteins and plays a crucial role in the regulation of immune responses. In this article, we will delve into the structure, activity, and applications of Recombinant Mouse BTNL2/BTL-II Protein.

Structure

Recombinant Mouse BTNL2/BTL-II Protein is a type I transmembrane protein, meaning that it spans the cell membrane once. It is composed of 6 extracellular immunoglobulin (Ig)-like domains, a transmembrane domain, and a cytoplasmic tail. The extracellular Ig-like domains are responsible for the interaction with other proteins, while the transmembrane domain anchors the protein to the cell membrane. The cytoplasmic tail is involved in signaling and regulation of immune responses.

Activity

Recombinant Mouse BTNL2/BTL-II Protein is primarily expressed on antigen-presenting cells, such as dendritic cells, macrophages, and B cells. It interacts with its receptor, the T cell immunoglobulin and mucin domain-containing protein 3 (Tim-3), on T cells and regulates their activation and differentiation. This interaction leads to the suppression of T cell proliferation and cytokine production, thereby playing a crucial role in maintaining immune homeostasis.

Moreover, Recombinant Mouse BTNL2/BTL-II Protein has been shown to induce the differentiation of regulatory T cells (Tregs) from naive CD4+ T cells. Tregs are a specialized subset of T cells that play a vital role in immune tolerance and preventing autoimmune diseases. This activity of Recombinant Mouse BTNL2/BTL-II Protein makes it a potential therapeutic target for the treatment of autoimmune diseases.

Applications

The recombinant form of BTNL2/BTL-II Protein has been widely used in various research studies to investigate its role in immune regulation. It has also been used to study the interaction between BTNL2/BTL-II Protein and its receptor, Tim-3, and the downstream signaling pathways involved. Additionally, recombinant BTNL2/BTL-II Protein has been used to generate monoclonal antibodies for further research and potential therapeutic applications.

One of the potential therapeutic applications of Recombinant Mouse BTNL2/BTL-II Protein is in the treatment of autoimmune diseases. As mentioned earlier, BTNL2/BTL-II Protein has been shown to induce Treg differentiation, which can help in suppressing the immune response and preventing autoimmune reactions. This has been demonstrated in a mouse model of multiple sclerosis, where administration of recombinant BTNL2/BTL-II Protein resulted in a significant reduction in disease severity.

Furthermore, Recombinant Mouse BTNL2/BTL-II Protein has also been investigated as a potential cancer immunotherapy. It has been shown to inhibit the growth and metastasis of various types of cancer, including lung, breast, and colon cancer. This is due to its ability to suppress T cell proliferation and cytokine production, which are essential for cancer cell growth and survival. Additionally, BTNL2/BTL-II Protein has been found to enhance the activity of natural killer cells, which play a crucial role in the immune response against cancer cells.

In conclusion, Recombinant Mouse BTNL2/BTL-II Protein is a promising protein that has been extensively studied for its role in immune regulation and potential therapeutic applications. Its structure, activity, and applications make it a valuable tool for further research and development of novel treatments for autoimmune diseases and cancer.